Literature DB >> 16299275

Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.

Daniela R Faria1, Kenneth J Gollob, José Barbosa, Albert Schriefer, Paulo R L Machado, Hélio Lessa, Lucas P Carvalho, Marco Aurélio Romano-Silva, Amélia R de Jesus, Edgar M Carvalho, Walderez O Dutra.   

Abstract

Human infection with Leishmania braziliensis can lead to cutaneous leishmaniasis (CL) or mucosal leishmaniasis (ML). We hypothesize that the intense tissue destruction observed in ML is a consequence of an uncontrolled exacerbated inflammatory immune response, with cytotoxic activity. For the first time, this work identifies the cellular sources of inflammatory and antiinflammatory cytokines, the expression of effector molecules, and the expression of interleukin-10 (IL-10) receptor in ML and CL lesions by using confocal microscopy. ML lesions displayed a higher number of gamma interferon (IFN-gamma)-producing cells than did CL lesions. In both ML and CL, CD4+ cells represented the majority of IFN-gamma-producing cells, followed by CD8+ cells and CD4- CD8- cells. The numbers of tumor necrosis factor alpha-positive cells, as well as those of IL-10-producing cells, were similar in ML and CL lesions. The effector molecule granzyme A showed greater expression in ML than in CL lesions, while inducible nitric oxide synthase did not. Finally, the expression of IL-10 receptor was lower in ML than in CL lesions. Thus, our data identified distinct cytokine and cell population profiles for CL versus ML patients and provide a possible mechanism for the development of ML disease through the demonstration that low expression of IL-10 receptor is present in conjunction with a cytotoxic and inflammatory profile in ML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299275      PMCID: PMC1307048          DOI: 10.1128/IAI.73.12.7853-7859.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Evidence of in situ cytotoxicity in American cutaneous leishmaniasis.

Authors:  Paulo Machado; Jean Kanitakis; Roque Almeida; Aurelie Chalon; Cibele Araújo; Edgar M Carvalho
Journal:  Eur J Dermatol       Date:  2002 Sep-Oct       Impact factor: 3.328

2.  CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.

Authors:  Yasmine Belkaid; Ciriaco A Piccirillo; Susana Mendez; Ethan M Shevach; David L Sacks
Journal:  Nature       Date:  2002-12-05       Impact factor: 49.962

Review 3.  The immunology of susceptibility and resistance to Leishmania major in mice.

Authors:  David Sacks; Nancy Noben-Trauth
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

4.  Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12.

Authors:  E Bourreau; G Prévot; R Pradinaud; P Launois
Journal:  J Infect Dis       Date:  2001-02-09       Impact factor: 5.226

5.  Up-regulation of Th1-type responses in mucosal leishmaniasis patients.

Authors:  Olívia Bacellar; Hélio Lessa; Albert Schriefer; Paulo Machado; Amélia Ribeiro de Jesus; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony.

Authors:  H A Lessa; P Machado; F Lima; A A Cruz; O Bacellar; J Guerreiro; E M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

7.  Interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD.

Authors:  M C Sasiain; S de la Barrera; S Fink; M Finiasz; M Alemán; M H Fariña; G Pizzariello; R Valdez
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 8.  Nitric oxide and chronic gut inflammation: controversies in inflammatory bowel disease.

Authors:  Matthew B Grisham; Kevin P Pavlick; F Stephen Laroux; Jason Hoffman; Sulaiman Bharwani; Robert E Wolf
Journal:  J Investig Med       Date:  2002-07       Impact factor: 2.895

Review 9.  Nitric oxide and atherosclerotic lesion progression: an overview.

Authors:  Claudio Napoli
Journal:  J Card Surg       Date:  2002 Jul-Aug       Impact factor: 1.620

Review 10.  Functional significance of the perforin/granzyme cell death pathway.

Authors:  Joseph A Trapani; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

View more
  105 in total

1.  FLI1 polymorphism affects susceptibility to cutaneous leishmaniasis in Brazil.

Authors:  L Castellucci; S E Jamieson; E N Miller; L F de Almeida; J Oliveira; A Magalhães; L H Guimarães; M Lessa; E Lago; A R de Jesus; E M Carvalho; J M Blackwell
Journal:  Genes Immun       Date:  2011-06-02       Impact factor: 2.676

2.  Characterization of regulatory T cell (Treg) function in patients infected with Leishmania braziliensis.

Authors:  Diego L Costa; Luiz H Guimarães; Thiago M Cardoso; Adriano Queiroz; Ednaldo Lago; Ana M Roselino; Olívia Bacellar; Edgar M Carvalho; João S Silva
Journal:  Hum Immunol       Date:  2013-08-28       Impact factor: 2.850

3.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

4.  Effector memory CD4(+) T cells differentially express activation associated molecules depending on the duration of American cutaneous leishmaniasis lesions.

Authors:  C de Oliveira Mendes-Aguiar; R Vieira-Gonçalves; L H Guimarães; M P de Oliveira-Neto; E M Carvalho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2016-06-06       Impact factor: 4.330

5.  CD4(+) T cells defined by their Vβ T cell receptor expression are associated with immunoregulatory profiles and lesion size in human leishmaniasis.

Authors:  T S L Keesen; L R V Antonelli; D R Faria; L H Guimarães; O Bacellar; E M Carvalho; W O Dutra; K J Gollob
Journal:  Clin Exp Immunol       Date:  2011-07-04       Impact factor: 4.330

6.  Early Cutaneous Leishmaniasis Patients Infected With Leishmania braziliensis Express Increased Inflammatory Responses After Antimony Therapy.

Authors:  Rúbia S Costa; Lucas P Carvalho; Taís M Campos; Andréa S Magalhães; Sara T Passos; Albert Schriefer; Juliana A Silva; Ednaldo Lago; Camilla S Paixão; Paulo Machado; Phillip Scott; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

7.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

8.  Age modifies the immunologic response and clinical presentation of American tegumentary leishmaniasis.

Authors:  Augusto M Carvalho; Camila F Amorim; Juliana L S Barbosa; Alexsandro S Lago; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

9.  Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.

Authors:  Aline C Muniz; Olívia Bacellar; Ednaldo Lima Lago; Augusto M Carvalho; Pedro Paulo Carneiro; Luiz Henrique Guimarães; Paulo N Rocha; Lucas P Carvalho; Marshall Glesby; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

10.  The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection.

Authors:  Allison Ehrlich; Tiago Moreno Castilho; Karen Goldsmith-Pestana; Wook-Jin Chae; Alfred L M Bothwell; Tim Sparwasser; Diane McMahon-Pratt
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.